Cancers Which Are CD44v6 Positive Clinical Trial
Official title:
Multi-center Phase I/II Clinical Trial of 4SCAR-CD44v6 T Cells for Treating Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.
CD44 variant domain 6 (CD44v6) which belongs to CD44 family has been implicated in
tumorigenesis, tumor cell invasion and metastasis. The expression of CD44v6 was reported for
the majority of squamous cell carcinomas, a proportion of adenocarcinomas of differing
origin, a proportion of melanoma and lymphoma. This expression pattern has made CD44v6 an
attractive target for the therapy of various types of CD44v6 positive cancers.
The T cells from patients or transplantation donors will be genetically modified with
lentiviral CAR vector to recognize specific molecules - CD44v6 expressed on the surface of
the cancer cells. The engineered T cells will be applied to patients through intravenous
delivery.
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of
CD44v6 CAR-T cell therapy in multiple cancers including - but not limited to - stomach
cancer, breast cancer, prostate cancer, multiple myeloma and lymphoma which are CD44v6
positive. Another goal of the study is to learn more about the function of the 4SCAR-CD44v6 T
cells and their persistency in the patients.
;